9 Meters Biopharma

9 Meters Biopharma is focused on rare and unmet needs in Gastroenterology.

ARC Therapeutics

ARC Therapeutics is a development-stage pharmaceutical company developing small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. The team’s unique insights about the biology and structure of CDKs will facilitate the rapid discovery and development of a novel, potent, and selective CDK2 inhibitor to treat patients whose tumors are insensitive to CDK4/6 inhibition.

The lead product candidate, AVB-500, is an ultra-high affinity decoy protein that starves the GAS6/AXL signaling pathway.

Aruna Bio is advancing a new class of cell-free biologics, exosomes, for the treatment of neurodegenerative disorders and leveraging a novel platform to optimize the delivery of RNAs, antibodies, genes and small molecules.

Liquidia Technologies (LQDA) is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.

Sapience Therapeutics is a clinical stage biotechnology company focused on developing its lead compound, ST101. The first clinical trial was initiated in July 2020. ST101 has been granted orphan drug designation for glioma and AML.

Carbon3D, a Silicon Valley based company, was founded in 2013 in Chapel Hill, NC. Working at the intersection of hardware, software and molecular science, Carbon3D is delivering on the promise of 3D printing, allowing commercial customers to go beyond basic prototyping to achieve 3D manufacturing.

A spinout from Duke University, developing immunotherapies for autoimmunity, cancer and immunodeficiency.

Developing "on demand" pharmaceuticals to restore voluntary control of bladder and bowel for people with spinal cord injury and neurological conditions.

Clinical-stage company developing small molecule therapies in the CDK4/6 & SERD categories to address significant unmet needs in oncology. GTHX, NASDAQ

An operating private equity fund that in-licenses drug candidates and develops through late-stage for ultimate sale to a commercializing company.

A clinical stage company developing opthalmic products in a novel delivery device.

An early stage company providing healthcare information to children/families using "super hero" comic formats.

A spinout from UNC, researching and developing novel cancer treatments, including MER Kinase inhibitors.